CC
Casdin Capital Portfolio holdings
AUM $1.1B
1-Year Return
24.98%
This Quarter Return
+24.58%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$2.23B
AUM Growth
+$544M
(+32%)
Cap. Flow
+$334M
Cap. Flow
% of AUM
14.94%
Top 10 Holdings %
Top 10 Hldgs %
63.09%
Holding
48
New
6
Increased
13
Reduced
3
Closed
3
Top Buys
| 1 |
Relay Therapeutics
RLAY
|
+$162M |
| 2 |
Pacific Biosciences
PACB
|
+$44.4M |
| 3 |
BioLife Solutions
BLFS
|
+$28.7M |
| 4 |
Agios Pharmaceuticals
AGIO
|
+$23.8M |
| 5 |
Taysha Gene Therapies
TSHA
|
+$18.4M |
Top Sells
| 1 |
GRTS
Gritstone bio, Inc. Common Stock
GRTS
|
+$12.3M |
| 2 |
BLUE
bluebird bio
BLUE
|
+$10.3M |
| 3 |
Voyager Therapeutics
VYGR
|
+$9.47M |
| 4 |
Codexis
CDXS
|
+$8.31M |
| 5 |
Zymeworks
ZYME
|
+$4.69M |
Sector Composition
| 1 | Healthcare | 80.87% |
| 2 | Materials | 0.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
NVTA
1
DELISTED
Invitae Corporation
NVTA
| $392M | 17.54% |
9,033,943
| – | – |
|
|
2
BioLife Solutions
BLFS
$1.24B
| $169M | 7.57% |
5,840,107
+990,583
| +20% | +$28.7M |
|
|
3
Relay Therapeutics
RLAY
$728M
| $162M | 7.26% |
+3,808,894
| New | +$162M |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $144M | 6.43% |
1,550,000
| – | – |
|
5
Fate Therapeutics
FATE
$111M
| $122M | 5.46% |
3,050,000
| – | – |
|
|
MYOK
6
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $119M | 5.31% |
870,000
| – | – |
|
7
Alnylam Pharmaceuticals
ALNY
$60.5B
| $90.3M | 4.04% |
620,000
+70,000
| +13% | +$10.2M |
|
8
Twist Bioscience
TWST
$1.58B
| $76M | 3.4% |
1,000,000
| – | – |
|
9
Sarepta Therapeutics
SRPT
$1.93B
| $74.4M | 3.33% |
530,000
| – | – |
|
|
10
Agios Pharmaceuticals
AGIO
$2.15B
| $61.3M | 2.74% |
1,750,000
+680,000
| +64% | +$23.8M |
|
11
Revolution Medicines
RVMD
$8.59B
| $56.9M | 2.55% |
1,634,535
+299,999
| +22% | +$10.4M |
|
12
Generation Bio
GBIO
$39.5M
| $49.8M | 2.23% |
161,121
| – | – |
|
|
BLUE
13
DELISTED
bluebird bio
BLUE
| $49.4M | 2.21% |
70,638
-14,668
| -17% | -$10.3M |
|
|
BNR
14
Burning Rock Biotech
BNR
$91.5M
| $48.2M | 2.16% |
192,215
+19,136
| +11% | +$4.8M |
|
15
Denali Therapeutics
DNLI
$1.95B
| $46.9M | 2.1% |
1,310,000
| – | – |
|
|
16
Codexis
CDXS
$222M
| $46.8M | 2.09% |
3,985,000
-707,732
| -15% | -$8.31M |
|
17
CareDx
CDNA
$752M
| $45.3M | 2.03% |
1,193,335
| – | – |
|
|
18
Pacific Biosciences
PACB
$363M
| $44.4M | 1.99% |
+4,500,000
| New | +$44.4M |
|
|
ONC
19
BeOne Medicines Ltd. American Depositary Shares
ONC
$35.9B
| $43M | 1.92% |
150,000
| – | – |
|
20
Allogene Therapeutics
ALLO
$264M
| $35.6M | 1.6% |
945,000
+320,000
| +51% | +$12.1M |
|
21
Adaptive Biotechnologies
ADPT
$1.98B
| $34.7M | 1.55% |
713,125
| – | – |
|
22
Adverum Biotechnologies
ADVM
$64M
| $28.3M | 1.27% |
275,000
+88,500
| +47% | +$9.12M |
|
23
Dianthus Therapeutics
DNTH
$1.51B
| $22.8M | 1.02% |
209,127
| – | – |
|
24
CRISPR Therapeutics
CRSP
$5.49B
| $22.3M | 1% |
266,430
| – | – |
|
|
GBT
25
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $21.8M | 0.98% |
395,000
+95,000
| +32% | +$5.24M |
|